Connor, Clark & Lunn Investment Management (CC&L)’s Atea Pharmaceuticals AVIR Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,985	Closed	-$69.9K	–	1639
2026 Q1	$69.9K	Buy	+12,985	New	+$59.6K	﹤0.01%	1509
2025 Q2	–	Sell	-30,087	Closed	-$90K	–	1505
2025 Q1	$90K	Sell	30,087 -46,265	-61%	-$144K	﹤0.01%	1356
2024 Q4	$256K	Buy	76,352 +32,195	+73%	+$107K	﹤0.01%	1284
2024 Q3	$148K	Buy	+44,157	New	+$160K	﹤0.01%	1350
2024 Q2	–	Sell	-67,111	Closed	-$271K	–	1378
2024 Q1	$271K	Buy	67,111 +14,979	+29%	+$58.6K	﹤0.01%	1302
2023 Q4	$159K	Sell	52,132 -38,826	-43%	-$118K	﹤0.01%	1285
2023 Q3	$273K	Buy	90,958 +2,816	+3%	+$9.58K	﹤0.01%	1167
2023 Q2	$330K	Buy	+88,142	New	+$330K	﹤0.01%	1085

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AVIR Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 12,985 shares — an estimated $69.9K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AVIR in Q2 2023 and held it in 8 quarters. The position peaked at $330K in Q2 2023. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 12,985 Atea Pharmaceuticals shares in Q2 2026, an estimated $69.9K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Atea Pharmaceuticals in Q2 2023 and held it in 8 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Atea Pharmaceuticals position peaked at $330K in Q2 2023.
124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.